Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Inclusion Criteria:

* Age ≥ 18 years old, voluntary consent and signed written informed consent
* ECOG 0\~2
* Pathologically diagnosed HER2-negative breast cancer patients with radiologically confirmed locally advanced (stage IIIB or IIIC) or metastatic (stage IV) breast cancer; HR-positive patients were permitted
* At least one measurable disease lesion before treatment
* Never receive Eribulin Mesylate treatment or anti-angiogenetic therapies before recruitment
* Anticipated survival time is longer than three months
* Brain metastases with stable disease or without clinical symptom
* Blood routine test, liver and kidney function test meet the following criteria: PLT \> 100g / L, Hb \> 9g / L, Neutrophil \> 2.0 g/L; AST and ALT \< 2.5 upper limit of normal (ULN); Cr \< 1.0 ULN; TBIL \< 1.5ULN
* Previously treated with anthracycline-based and taxane-based chemotherapy regimens (at least one line of chemotherapy in the metastatic setting or the recurrence time is less than 1 year from the end of adjuvant or neoadjuvant chemotherapy); for HR-positive/HER2-negative patients, progressed after at least one line of endocrine therapy
* For women with fertility, the pregnancy test before administration was negative, and agreed to take appropriate measures to avoid pregnancy during the study treatment and at least half a year after the end of treatment; Men agreed to take appropriate contraceptive measures during the study treatment and at least half a year after the end of the treatment.

Exclusion Criteria:

* Pregnant or lactating women
* Active infection requiring systemic treatment
* HIV positive
* Suffering from or suspected of suffering from central neuromuscular system diseases
* Serious heart disease; uncontrollable hypertension; history of heavy hemorrhea；recent operation within three months
* The investigator considered that the patient was not suitable for in this study, with any other situation.